Infections with Candida spp. cause significant morbidity and mortality despite intensive treatment with antifungal agents. Novel treatment options are urgently needed. Predominately immunocompromised patients are affected. This warrants the conclusion that strengthening host immunity may have the potential to improve outcome. Recent studies imply a potential benefit of checkpoint inhibition reversing hyporesponsiveness of innate and adaptive immunity during invasive fungal infections and invasive candidiasis in particular. We here give a brief overview of first preclinical data in vitro and in vivo and clinical evidence in selected cases.
Invasive candidiasis causes significant morbidity and mortality despite intensive treatment with antifungal agents. [1] [2] [3] Severely ill and immunocompromised patients are affected in particular, 4, 5 and mortality in those patients exceeds that of infections with bacterial pathogens. 6, 7 Between 1988 and 2003, mortality attributable to invasive candidiasis has not decreased in spite of new diagnostic methods, novel antifungal treatment options, and improved infection control. 1, 3 New management options are urgently needed. The fact that predominately immunocompromised patients are affected warrants the conclusion that strengthening host immunity may have the potential to improve outcome. This hypothesis is supported by preclinical data in vitro and in vivo and first clinical evidence in selected cases.
While administration of interleukin 7 (IL-7) and interferon γ (IFN-γ ) were shown to restore immunity in mice 8 and humans, 9 recent studies imply a potential benefit of checkpoint inhibition in invasive fungal infections and invasive candidiasis in particular. [10] [11] [12] [13] [14] Immune activation is regulated by positive and negative costimulatory molecules, which have been termed Immune checkpoints due to their central regulatory function. Some of these molecules exert an inhibitory function limiting immune response and allowing self-tolerance. [15] [16] [17] [18] The checkpoint programmed cell death 1 (PD1) is a member of the B7-CD28 superfamily and is expressed on T-and B-lymphocytes, monocytes, and natural killer (NK) cells after activation. 19 To date, PD1-L1 (B7-H1) and PD1-L2 (B7-DC) have been identified as ligands of PD1. Both ligands are expressed on antigen-presenting cells and PD1-L1 is additionally detected on the surface of various nonhematopoietic cells including tumor cells. Binding of PD1 to its ligands inhibits T-cell receptor signaling on activated T-lymphocytes and impairs T-cell functions such as cytokine production and cytotoxic activity. PD1-deficient mice developing fatal autoimmune diseases underscore the essential role of PD1 in immune balance. 20 Inhibition of the PD-1-PD-L1 axis restores immunity ( Fig. 1 ) and is used in cancer therapy with great success. [21] [22] [23] [24] [25] [26] [27] CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) is another inhibitory immune checkpoint, which is expressed during the T-cell priming phase (Fig. 2) . 28 Ipilimumab, an anti-CTLA-4 antibody, is superior to standard chemotherapy in metastatic melanoma and was the first immune checkpoint inhibitor approved for the treatment of cancer patients. 29 Based on the aforementioned preclinical studies, 10, [12] [13] [14] 30 there is significant evidence supporting that immunosuppression is detrimental during invasive fungal infection. The effects of immune checkpoint inhibition on survival and IFN-γ production were examined in a mouse model of fungal sepsis 24 to 48 h after infection. 10 Administration of an anti-PD1-antibody improved survival effectively by reversing sepsis-induced suppression of interferon γ . These results are in line with previous studies showing that blockade of PD-1 and CTLA-4 improves survival in bacterial sepsis. 30 Targeting inhibitory immune checkpoints, to reverse hyporesponsiveness of innate and adaptive immunity during invasive fungal infection, appears promising. However, such therapy needs to be individualized based on the immune status of each patient.
Expression of immune checkpoints during candidemia was reported in a small number of patients (n = 27) for the first time in humans recently. 13 Nonseptic critically ill patients without evidence of bacterial or fungal infection served as controls. CD8 T cells from patients with candidemia showed cellular activation as indicated by increased CD69 expression. Expression of CD28, the major positive co-stimulatory molecule, was decreased on CD4 T cells. CD4 and CD8 T cells from candidemia patients showed increased expression of exhaustion markers such as PD1 or PD-L1. The first patient treated with an immune checkpoint inhibitor for invasive fungal infection was reported in 2017: 11 a polytrauma patient with mucormycosis received the drug in a desperate clinical situation and recovered. A benefit of immune-checkpoint inhibitors in invasive fungal infection other than mucormycosis can be assumed, but needs further investigation.
Immunosuppression as well as abdominal surgery and treatment at an intensive care unit represent major risk factors for candidemia. 31, 32 These conditions define the potential target population for treatment with immune checkpoint inhibitors. Yet it remains to be investigated if patients with neutropenia may benefit from this approach. The fact that lymphocytopenia is never absolute and many patients still have functional lymphocytes during neutropenia, in particular, T cells, 33 indicates a possible role also in this subpopulation. Patients with autoimmune disorders, chronic viral infections, ongoing immunosuppressant use, organ dysfunction, impaired functional status, and organ transplant patients constitute further challenging populations. 33, 34 Use of ICI may entail severe, most commonly autoimmune, adverse effects. We envision salvage treatment as a starting point. The risk-benefit ratio must be evaluated individually, but may be acceptable in most cases due to high mortality of candidemia.
While Spec et al. have reported an increased level of PD1-expression on T cells during candidemia, 13 this was only a small subset of patients and a correlation between PD1-expression level and outcome was missing. Also, checkpoint-expression in the microenvironment of ICI would be of utmost interest. Translational analyses observing immune checkpoint expression and T-cell exhaustion during invasive fungal infection could provide further evidence for a tailored design of clinical trials investigating immune checkpoint inhibition in the treatment of invasive mycosis. The association of immunosuppression and susceptibility to fungal infection or poor outcome emphasize the potential role of immunotherapy. Immune checkpoint inhibitors and several already approved or currently evaluated immunotherapeutic drugs offer unprecedented chances for exploiting existing treatment approaches for fungal disease.
